Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
UNC Lineberger Comprehensive Cancer Center
AstraZeneca
Case Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Vanderbilt-Ingram Cancer Center
National Institutes of Health Clinical Center (CC)
McGuire Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Neonc Technologies, Inc.
Seoul National University Bundang Hospital
Salzburger Landeskliniken
UNC Lineberger Comprehensive Cancer Center
Abramson Cancer Center at Penn Medicine
University of Maryland, Baltimore
Washington University School of Medicine
Merck Sharp & Dohme LLC
University of Chicago
NRG Oncology
Massachusetts General Hospital
University of Colorado, Denver
H. Lee Moffitt Cancer Center and Research Institute
Wake Forest University Health Sciences
UNC Lineberger Comprehensive Cancer Center
VA Office of Research and Development
Royal Marsden NHS Foundation Trust
Maia Biotechnology
VLP Therapeutics
University of Chicago
Onchilles Pharma Inc
Ocellaris Pharma, Inc.
Maia Biotechnology
University of Pittsburgh
H. Lee Moffitt Cancer Center and Research Institute
Mashhad University of Medical Sciences
Centre Henri Becquerel
Memorial Sloan Kettering Cancer Center
Institut de Cancérologie de Lorraine
Mayo Clinic
H. Lee Moffitt Cancer Center and Research Institute